Coherus BioSciences (CHRS) Stock Forecast, Price Target & Predictions
CHRS Stock Forecast
Coherus BioSciences stock forecast is as follows: an average price target of $9.00 (represents a 1144.81% upside from CHRS’s last price of $0.72) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
CHRS Price Target
The average price target for Coherus BioSciences (CHRS) is $9.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $7.00. This represents a potential 1144.81% upside from CHRS's last price of $0.72.
CHRS Analyst Ratings
According to 5 Wall Street analysts, Coherus BioSciences's rating consensus is 'Hold'. The analyst rating breakdown for CHRS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 3 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Coherus BioSciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 14, 2022 | - | J.P. Morgan | $11.00 | $7.79 | 41.21% | 1421.44% |
| Jun 13, 2022 | Ashwani Verma | UBS | $7.00 | $6.19 | 13.09% | 868.19% |
The latest Coherus BioSciences stock forecast, released on Nov 14, 2022 by J.P. Morgan company, set a price target of $11.00, which represents a 41.21% increase from the stock price at the time of the forecast ($7.79), and a 1421.44% increase from CHRS last price ($0.72).
Coherus BioSciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.72 | $0.72 | $0.72 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Coherus BioSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Coherus BioSciences's last price of $0.72. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 16, 2024 | UBS | Buy | Neutral | Downgrade |
| May 30, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 28, 2023 | UBS | Neutral | Buy | Upgrade |
| Jun 13, 2022 | UBS | - | Neutral | Initialise |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
| Apr 26, 2022 | J.P. Morgan | - | Neutral | Downgrade |
Coherus BioSciences's last stock rating was published by UBS on Aug 16, 2024. The company Downgrade its CHRS rating from "Buy" to "Neutral".
Coherus BioSciences Financial Forecast
Coherus BioSciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $91.52M | $74.57M | $58.72M | $32.44M | $45.35M | $45.42M | $60.15M | $60.12M | $73.37M | $82.50M | $87.64M | $83.03M | $110.42M | $113.55M | $135.67M | $116.18M | $123.86M | $111.68M | $83.43M | $37.10M | $161.00K | $12.36M |
| Avg Forecast | $80.40M | $75.90M | $70.25M | $65.75M | $60.26M | $58.98M | $62.06M | $81.70M | $96.89M | $81.78M | $50.47M | $46.29M | $47.69M | $56.69M | $62.04M | $69.54M | $82.61M | $90.69M | $87.04M | $96.20M | $114.89M | $124.01M | $102.52M | $119.44M | $125.09M | $100.72M | $64.63M | $36.96M | $143.23K | $10.51M |
| High Forecast | $80.40M | $75.90M | $70.25M | $65.75M | $60.26M | $75.02M | $62.06M | $81.70M | $111.89M | $81.78M | $50.47M | $46.29M | $47.69M | $56.69M | $62.04M | $69.54M | $82.61M | $90.69M | $87.04M | $96.20M | $114.89M | $124.01M | $102.52M | $119.44M | $125.09M | $100.72M | $64.63M | $36.96M | $171.87K | $12.61M |
| Low Forecast | $80.40M | $75.90M | $70.25M | $65.75M | $60.26M | $31.11M | $62.06M | $81.70M | $81.90M | $81.78M | $50.47M | $46.29M | $47.69M | $56.69M | $62.04M | $69.54M | $82.61M | $90.69M | $87.04M | $96.20M | $114.89M | $124.01M | $102.52M | $119.44M | $125.09M | $100.72M | $64.63M | $36.96M | $114.58K | $8.41M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | 0.94% | 0.91% | 1.16% | 0.70% | 0.95% | 0.80% | 0.97% | 0.86% | 0.89% | 0.91% | 1.01% | 0.86% | 0.96% | 0.92% | 1.32% | 0.97% | 0.99% | 1.11% | 1.29% | 1.00% | 1.12% | 1.18% |
Coherus BioSciences's average Quarter revenue forecast for Mar 24 based on 3 analysts is $81.70M, with a low forecast of $81.70M, and a high forecast of $81.70M. CHRS's average Quarter revenue forecast represents a -10.73% decrease compared to the company's last Quarter revenue of $91.52M (Dec 23).
Coherus BioSciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | $-68.36M | $-32.01M | $-34.54M | $-66.02M | $-49.48M | $-78.11M | $-42.68M | $-80.13M | $-39.10M | $-31.86M | $-23.28M | $-166.45M | $17.27M | $34.47M | $66.48M | $41.54M | $46.81M | $53.20M | $28.73M | $-15.10M | $-71.54M | $-63.83M |
| Avg Forecast | $-30.64M | $-28.93M | $-26.77M | $-25.06M | $-22.97M | $-22.48M | $-23.65M | $-88.66M | $-36.93M | $-31.17M | $-19.24M | $-70.09M | $-43.71M | $-21.61M | $-23.64M | $-55.41M | $-31.48M | $-34.56M | $-33.17M | $-5.84B | $-43.78M | $-47.26M | $-39.07M | $47.48M | $-47.67M | $-38.39M | $-24.63M | $-20.88M | $-62.66M | $-52.60M |
| High Forecast | $-30.64M | $-28.93M | $-26.77M | $-25.06M | $-22.97M | $-11.86M | $-23.65M | $-70.93M | $-31.21M | $-31.17M | $-19.24M | $-56.07M | $-34.97M | $-21.61M | $-23.64M | $-44.33M | $-31.48M | $-34.56M | $-33.17M | $-4.67B | $-43.78M | $-47.26M | $-39.07M | $56.97M | $-47.67M | $-38.39M | $-24.63M | $-16.70M | $-50.13M | $-42.08M |
| Low Forecast | $-30.64M | $-28.93M | $-26.77M | $-25.06M | $-22.97M | $-28.59M | $-23.65M | $-106.40M | $-42.64M | $-31.17M | $-19.24M | $-84.11M | $-52.45M | $-21.61M | $-23.64M | $-66.49M | $-31.48M | $-34.56M | $-33.17M | $-7.01B | $-43.78M | $-47.26M | $-39.07M | $37.98M | $-47.67M | $-38.39M | $-24.63M | $-25.05M | $-75.19M | $-63.11M |
| Surprise % | - | - | - | - | - | - | - | - | 1.85% | 1.03% | 1.80% | 0.94% | 1.13% | 3.62% | 1.81% | 1.45% | 1.24% | 0.92% | 0.70% | 0.03% | -0.39% | -0.73% | -1.70% | 0.88% | -0.98% | -1.39% | -1.17% | 0.72% | 1.14% | 1.21% |
3 analysts predict CHRS's average Quarter EBITDA for Mar 21 to be $-5.84B, with a high of $-4.67B and a low of $-7.01B. This is -33927.77% lower than Coherus BioSciences's previous annual EBITDA (Dec 20) of $17.27M.
Coherus BioSciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
| Net Income | - | - | - | - | - | - | - | - | $-79.65M | $-39.64M | $-42.87M | $-74.78M | $-66.25M | $-92.85M | $-56.29M | $-111.24M | $-51.52M | $-38.53M | $-29.90M | $-172.95M | $9.71M | $27.93M | $59.03M | $35.57M | $39.23M | $47.04M | $23.57M | $-20.00M | $-74.78M | $-65.39M |
| Avg Forecast | $-5.74M | $-5.74M | $-5.74M | $-5.74M | $-24.85M | $-18.76M | $-28.55M | $-98.66M | $-22.83M | $-44.82M | $-72.21M | $-77.99M | $-51.12M | $-82.31M | $-89.99M | $-61.65M | $-52.82M | $-39.73M | $-24.11M | $-6.07B | $24.68M | $42.04M | $33.20M | $40.65M | $80.89M | $54.62M | $-4.25M | $-27.67M | $-65.50M | $-53.88M |
| High Forecast | $-5.74M | $-5.74M | $-5.74M | $-5.74M | $-24.85M | $-18.76M | $-28.55M | $-78.93M | $-22.83M | $-44.82M | $-72.21M | $-62.39M | $-40.90M | $-82.31M | $-89.99M | $-49.32M | $-52.82M | $-39.73M | $-24.11M | $-4.86B | $24.68M | $42.04M | $33.20M | $48.78M | $80.89M | $54.62M | $-4.25M | $-22.13M | $-52.40M | $-43.10M |
| Low Forecast | $-5.74M | $-5.74M | $-5.74M | $-5.74M | $-24.85M | $-18.76M | $-28.55M | $-118.39M | $-22.83M | $-44.82M | $-72.21M | $-93.59M | $-61.35M | $-82.31M | $-89.99M | $-73.98M | $-52.82M | $-39.73M | $-24.11M | $-7.28B | $24.68M | $42.04M | $33.20M | $32.52M | $80.89M | $54.62M | $-4.25M | $-33.20M | $-78.60M | $-64.65M |
| Surprise % | - | - | - | - | - | - | - | - | 3.49% | 0.88% | 0.59% | 0.96% | 1.30% | 1.13% | 0.63% | 1.80% | 0.98% | 0.97% | 1.24% | 0.03% | 0.39% | 0.66% | 1.78% | 0.88% | 0.48% | 0.86% | -5.55% | 0.72% | 1.14% | 1.21% |
Coherus BioSciences's average Quarter net income forecast for Mar 21 is $-6.07B, with a range of $-7.28B to $-4.86B. CHRS's average Quarter net income forecast represents a -62630.28% decrease compared to the company's last Quarter net income of $9.71M (Dec 20).
Coherus BioSciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
| SG&A | - | - | - | - | - | - | - | - | $48.95M | $48.22M | $45.14M | $49.15M | $53.62M | $44.83M | $51.28M | $48.75M | $50.05M | $39.92M | $40.34M | $39.39M | $37.69M | $31.98M | $34.05M | $35.35M | $36.07M | $31.83M | $36.46M | $32.68M | $18.80M | $11.40M |
| Avg Forecast | $45.97M | $43.40M | $40.17M | $37.59M | $34.46M | $33.72M | $35.48M | $50.06M | $55.40M | $46.76M | $28.86M | $39.57M | $27.27M | $32.42M | $35.47M | $31.28M | $47.24M | $51.85M | $49.77M | $55.01M | $65.69M | $70.91M | $58.62M | $40.40M | $71.52M | $57.59M | $36.95M | $21.13M | $81.89K | $9.39M |
| High Forecast | $45.97M | $43.40M | $40.17M | $37.59M | $34.46M | $42.89M | $35.48M | $60.07M | $63.98M | $46.76M | $28.86M | $47.49M | $27.27M | $32.42M | $35.47M | $37.54M | $47.24M | $51.85M | $49.77M | $55.01M | $65.69M | $70.91M | $58.62M | $48.48M | $71.52M | $57.59M | $36.95M | $21.13M | $98.27K | $11.27M |
| Low Forecast | $45.97M | $43.40M | $40.17M | $37.59M | $34.46M | $17.79M | $35.48M | $40.05M | $46.83M | $46.76M | $28.86M | $31.66M | $27.27M | $32.42M | $35.47M | $25.03M | $47.24M | $51.85M | $49.77M | $55.01M | $65.69M | $70.91M | $58.62M | $32.32M | $71.52M | $57.59M | $36.95M | $21.13M | $65.51K | $7.51M |
| Surprise % | - | - | - | - | - | - | - | - | 0.88% | 1.03% | 1.56% | 1.24% | 1.97% | 1.38% | 1.45% | 1.56% | 1.06% | 0.77% | 0.81% | 0.72% | 0.57% | 0.45% | 0.58% | 0.88% | 0.50% | 0.55% | 0.99% | 1.55% | 229.60% | 1.21% |
Coherus BioSciences's average Quarter SG&A projection for Mar 24 is $50.06M, based on 3 Wall Street analysts, with a range of $40.05M to $60.07M. The forecast indicates a 2.27% rise compared to CHRS last annual SG&A of $48.95M (Dec 23).
Coherus BioSciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
| EPS | - | - | - | - | - | - | - | - | $-0.71 | $-0.00 | $-0.49 | $-0.94 | $-0.85 | $-1.19 | $-0.73 | $-1.44 | $-0.67 | $-0.49 | $-0.40 | $-2.37 | $0.13 | $0.39 | $0.83 | $0.50 | $0.56 | $0.67 | $0.34 | $-0.29 | $-1.54 | $-1.67 |
| Avg Forecast | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.22 | $-0.16 | $-0.25 | $-0.25 | $-0.20 | $-0.39 | $-0.63 | $-0.72 | $-0.98 | $-0.72 | $-0.78 | $-0.65 | $-0.46 | $-0.35 | $-0.21 | $-0.21 | $0.21 | $0.37 | $0.29 | $0.52 | $0.70 | $0.48 | $-0.04 | $-0.47 | $-1.20 | $-1.17 |
| High Forecast | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.22 | $-0.16 | $-0.25 | $-0.25 | $-0.20 | $-0.39 | $-0.63 | $-0.72 | $-0.98 | $-0.72 | $-0.78 | $-0.65 | $-0.46 | $-0.35 | $-0.21 | $-0.21 | $0.21 | $0.37 | $0.29 | $0.52 | $0.70 | $0.48 | $-0.04 | $-0.47 | $-0.96 | $-0.94 |
| Low Forecast | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.22 | $-0.16 | $-0.25 | $-0.25 | $-0.20 | $-0.39 | $-0.63 | $-0.72 | $-0.98 | $-0.72 | $-0.78 | $-0.65 | $-0.46 | $-0.35 | $-0.21 | $-0.21 | $0.21 | $0.37 | $0.29 | $0.52 | $0.70 | $0.48 | $-0.04 | $-0.47 | $-1.44 | $-1.40 |
| Surprise % | - | - | - | - | - | - | - | - | 3.57% | 0.00% | 0.78% | 1.30% | 0.87% | 1.66% | 0.93% | 2.23% | 1.46% | 1.42% | 1.90% | 11.47% | 0.60% | 1.07% | 2.87% | 0.97% | 0.79% | 1.41% | -9.19% | 0.62% | 1.28% | 1.43% |
According to 3 Wall Street analysts, Coherus BioSciences's projected average Quarter EPS for Mar 21 is $-0.21, with a low estimate of $-0.21 and a high estimate of $-0.21. This represents a -259.00% decrease compared to CHRS previous annual EPS of $0.13 (Dec 20).
Coherus BioSciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CHRS | Coherus BioSciences | $0.72 | $9.00 | 1150.00% | Hold |
| SPRO | Spero Therapeutics | $1.18 | $10.00 | 747.46% | Buy |
| CTMX | CytomX Therapeutics | $1.05 | $5.77 | 449.52% | Buy |
| NUVB | Nuvation Bio | $2.30 | $6.75 | 193.48% | Buy |
| TIL | Instil Bio | $28.78 | $78.25 | 171.89% | Hold |
| NXTC | NextCure | $1.33 | $3.00 | 125.56% | Buy |
| ASMB | Assembly Biosciences | $16.89 | $35.50 | 110.18% | Buy |
| ACHL | Achilles Therapeutics | $1.02 | $2.00 | 96.08% | Buy |
| BOLT | Bolt Biotherapeutics | $0.66 | $1.00 | 51.52% | Hold |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
CHRS Forecast FAQ
Is Coherus BioSciences a good buy?
No, according to 5 Wall Street analysts, Coherus BioSciences (CHRS) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of CHRS's total ratings.
What is CHRS's price target?
Coherus BioSciences (CHRS) average price target is $9 with a range of $7 to $11, implying a 1144.81% from its last price of $0.723. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Coherus BioSciences stock go up soon?
According to Wall Street analysts' prediction for CHRS stock, the company can go up by 1144.81% (from the last price of $0.723 to the average price target of $9), up by 1421.44% based on the highest stock price target, and up by 868.19% based on the lowest stock price target.
Can Coherus BioSciences stock reach $1?
CHRS's average twelve months analyst stock price target of $9 supports the claim that Coherus BioSciences can reach $1 in the near future.
What are Coherus BioSciences's analysts' financial forecasts?
Coherus BioSciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $263.01M (high $279.04M, low $235.14M), average EBITDA is $-158M (high $-129M, low $-182M), average net income is $-171M (high $-151M, low $-191M), average SG&A $153.73M (high $172.91M, low $127.78M), and average EPS is $-0.882 (high $-0.882, low $-0.882). CHRS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $292.3M (high $292.3M, low $292.3M), average EBITDA is $-111M (high $-111M, low $-111M), average net income is $-22.964M (high $-22.964M, low $-22.964M), average SG&A $167.13M (high $167.13M, low $167.13M), and average EPS is $-0.2 (high $-0.2, low $-0.2).
Did the CHRS's actual financial results beat the analysts' financial forecasts?
Based on Coherus BioSciences's last annual report (Dec 2023), the company's revenue was $257.24M, which missed the average analysts forecast of $275.44M by -6.61%. Apple's EBITDA was $-203M, beating the average prediction of $-157M by 29.08%. The company's net income was $-238M, beating the average estimation of $-218M by 9.20%. Apple's SG&A was $186.92M, beating the average forecast of $170.59M by 9.57%. Lastly, the company's EPS was $-2.53, beating the average prediction of $-1.939 by 30.46%. In terms of the last quarterly report (Dec 2023), Coherus BioSciences's revenue was $91.52M, missing the average analysts' forecast of $96.89M by -5.54%. The company's EBITDA was $-68.36M, beating the average prediction of $-36.926M by 85.12%. Coherus BioSciences's net income was $-79.653M, beating the average estimation of $-22.825M by 248.97%. The company's SG&A was $48.95M, missing the average forecast of $55.4M by -11.65%. Lastly, the company's EPS was $-0.71, beating the average prediction of $-0.199 by 257.16%